HISAMITSU PHARMA, The Current Fiscal Year Ordinary Profit Revised Upward to an Unexpected 17% Increase

About Information Provided on This Site

The information provided on our website 'Kabutan.com' is not intended to constitute investment solicitation or investment advisory services.
All investment decisions should be made at your own discretion and judgment.
The data on our website is provided by Tokyo Stock Exchange, Osaka Exchange, Nagoya Securities Exchange, JPX Market Innovation & Research, Japannext, and other sources.
Copyright of the Nikkei Stock Average belongs to Nikkei Inc. Stock price charts displayed on Kabutan.com are provided solely for the purpose of reviewing historical price movements of the securities.
These charts neither suggest nor guarantee future price movements of the securities and do not constitute recommendations to buy or sell.
In our financial results coverage, the term 'Surprise Results' identifies securities that demonstrate a significant degree of surprise in their earnings announcements.
This significance is quantitatively assessed based on multiple factors, including: the nature of the announcement (full-year or quarterly results); types of revisions (earnings or dividend forecasts); and numerical analysis comparing the announced results with both the company's previous forecasts and historical performance.
The 'Surprise Ranking' presents these results in order of their calculated surprise factor. Please note that neither these results nor rankings are intended to suggest or guarantee future performance of the listed securities, nor should they be construed as recommendations to buy or sell.

Thu Jan 9, 2025 3:30 pm JST Earnings

4530 HISAMITSU PHARMACEUTICAL CO.,INC. 【J-GAAP】

Earnings Report

HISAMITSU PHARMACEUTICAL CO.,INC. <4530> [TSE Prime] announced its financial results after the market closed on January 9th (15:30). The consolidated ordinary profit for the cumulative third quarter of the fiscal year ending February 2025 (March to November) was 16.4 billion yen, a 1.0% decrease compared to the same period last year.

However, the full-year consolidated ordinary profit has been revised upward 21.7%, from the previous forecast of 18.9 billion yen to 23 billion yen (compared to 19.6 billion yen in the previous period), turning to a 17.1% increase in the consolidated ordinary profit outlook.

Based on the full-year plan announced by the company after the upward revision, our estimate of the consolidated ordinary profit for the September to February period (2H) is expected to increase 50.5%, from the previous forecast of 8.11 billion yen to 12.2 billion yen (compared to 8 billion yen in the same period of the previous year), increasing the growth rate from 1.3% to 52.5%.

In the most recent three-month period, from September to November (3Q), the consolidated ordinary profit grew 13.7% from the same period last year, reaching 5.68 billion yen. The operating profit margin rose from 10.7% in the same period last year to 11.8%.

Kabutan News

Actual Results

Accumulated Results 3rd Quarter

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Progress Rate vs. First Half	Announce	Accounting Standards
Mar - Nov, 2022	91,881	8,506	13,003	9,522	119.5	81.0	Jan 12, 2023	J-GAAP
Mar - Nov, 2023	102,827	12,246	16,638	12,092	156.4	84.7	Jan 11, 2024	J-GAAP
Mar - Nov, 2024	111,253	13,220	16,471	13,660	185.0	71.6	Jan 9, 2025	J-GAAP
YoY	+8.2%	+8.0%	-1.0%	+13.0%	+18.3%

Guidance Update

Second Half Update

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Sep - Feb, 2024 Prev	76,544	5,494	8,112	6,702	91.9	45	Oct 10, 2024	J-GAAP
Sep - Feb, 2024 New	78,544	8,994	12,212	11,402	156.3	45	Jan 9, 2025	J-GAAP
Revision Rate	+2.6%	+63.7%	+50.5%	+70.1%	+70.1%

Full Year Update

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Feb, 2025 Prev	152,000	14,500	18,900	15,800	216.6	90	Apr 11, 2024	J-GAAP
Feb, 2025 New	154,000	18,000	23,000	20,500	281.1	90	Jan 9, 2025	J-GAAP
Revision Rate	+1.3%	+24.1%	+21.7%	+29.7%	+29.7%

Current Period Guidance

Second Half Results

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Sep - Feb, 2023	74,729	4,771	8,009	5,552	72.2	42.50	Apr 11, 2024	J-GAAP
Sep - Feb, 2024 Guidance	78,544	8,994	12,212	11,402	156.3	45	Jan 9, 2025	J-GAAP
YoY	+5.1%	+88.5%	+52.5%	+105.4%	+116.6%

Current Period Guidance

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Feb, 2023	128,330	11,599	16,051	11,742	148.0	84.50	Apr 13, 2023	J-GAAP
Feb, 2024	141,706	13,167	19,649	13,969	181.6	85	Apr 11, 2024	J-GAAP
Feb, 2025 Guidance	154,000	18,000	23,000	20,500	281.1	90	Jan 9, 2025	J-GAAP
YoY	+8.7%	+36.7%	+17.1%	+46.8%	+54.8%

Quarterly Results

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Operating Profit Margin	Announce	Accounting Standards
Sep - Nov, 2023	35,850	3,850	4,998	3,675	47.5	10.7	Jan 11, 2024	J-GAAP
Dec - Feb, 2023	38,879	921	3,011	1,877	24.4	2.4	Apr 11, 2024	J-GAAP
Mar - May, 2024	35,810	4,149	5,562	4,788	63.9	11.6	Jul 11, 2024	J-GAAP
Jun - Aug, 2024	39,646	4,857	5,226	4,310	58.1	12.3	Oct 10, 2024	J-GAAP
Sep - Nov, 2024	35,797	4,214	5,683	4,562	61.8	11.8	Jan 9, 2025	J-GAAP
YoY	-0.1%	+9.5%	+13.7%	+24.1%	+30.0%